March 30, 2021
Lizzie Aby
Share
To read the full article: https://www.nejm.org/doi/full/10.1056/nejmoa1509840
Can seladelpar serve as second-line treatment for PBC patients with inadequate UDCA therapy?
October 27, 2025
A new second-line therapy for Primary Biliary Cholangitis: Elafibranor
December 13, 2024
SCOPE Index
October 23, 2022
